Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20974448 | 1.00 | METAP2 (0.45) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL23206123 | 0.83 | METAP2 (0.47) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL21196238 | 0.78 | IDO1 (0.48) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL29344861 | 0.78 | METAP2 (0.43) | METAP2CYP1A2IDO1TDO2AXL | |
| SCHEMBL24971018 | 0.78 | METAP2 (0.43) | METAP2CYP1A2PTPN6IDO1AXL | |
| SCHEMBL19948646 | 0.77 | IDO1 (0.47) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL30410207 | 0.77 | IDO1 (0.47) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL29344213 | 0.76 | METAP2 (0.44) | METAP2CYP1A2PTPN6IDO1TDO2 | |
| SCHEMBL29344562 | 0.75 | TRPA1 (0.45) | METAP2CYP1A2AXLTRPA1TRPM8 | |
| SCHEMBL29344290 | 0.74 | METAP2 (0.38) | METAP2CYP1A2PTPN6IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713330-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025217319-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235286-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED LIMITED (CN) | 2024-11-21 | — | — | WO | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024233776-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118302162-A | Small molecule inhibitors of KRAS muteins | 默沙东有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024123102-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | 에스케이바이오팜 주식회사 | 2024-06-13 | — | — | WO | disclosed |
| WO-2024103010-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4347041-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Taiho Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117769554-A | Small molecule inhibitors of KRAS muteins | 大鹏药品工业株式会社 | 2024-03-26 | — | — | CN | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022250170-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |